Effect of atorvastatin combined with benazepril on proteinuria of patients with IgA nephropathy
10.3760/cma.j.issn.1008-6706.2018.10.022
- VernacularTitle:阿托伐他汀联合贝那普利对IgA肾病患者蛋白尿的影响
- Author:
Yuna LE
1
Author Information
1. 宁波市北仑区妇幼保健院内科
- Keywords:
Glomerulonephritis;
IgA;
Atorvastatin;
Benazepril;
Proteinuria
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(10):1307-1310
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of atorvastatin combined with benazepril in the treatment of proteinuria in patients with IgA nephropathy ,so as to provide guidance for clinical medication .Methods Eighty patients with IgA nephropathy were selected ,and they were randomly divided into the observation group and control group according to random number table , with 40 patients in each group .The observation group was treated with atorvastatin combined with benazepril ,and the control group was treated with benazepril .The treatment effect of the two groups was compared.Results Before treatment,the 24h urinary protein,mean arterial pressure,serum creat-inine,blood urea nitrogen,and blood potassium between the two groups had no statistically significant differences (t=0.125,1.273,0.321,0.207,0.719,all P>0.05).After treatment,the 24h urine protein and mean arterial blood pressure in the two groups were lower than those before treatment , and the differences were statistically significant (t=2.735,6.145,3.434,4.501,all P<0.05),which in the observation group were lower than those in the control group,the differences were statistically significant (t=3.121,2.170,all P<0.05).The changes of serum creatinine, blood urea nitrogen and serum potassium in the two groups had no statistically significant differences (all P>0.05) .Conclusion Atorvastatin combined with benazepril in the treatment of IgA nephropathy can significantly decrease urinary protein level,without the adverse reactions of increased urea nitrogen ,creatinine and hyperkalemia ,which is worthy of popularization and application .
